• Vaccine Name: live attenuated Brucella abortus BLS PrpA Omp19 SodC Salmonella Typhimurium vector vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009403
• Type: Live attenuated vaccine + Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Goat
• Antigen: BLS; PrpA; Omp19; SOD
• Preparation: Attenuated Salmonella Typhimurium vector expressing Brucella lumazine synthase (BLS), proline racemase subunit A (PrpA), outer-membrane protein 19 (Omp19), and Cu/Zn superoxide dismutase (SOD); administered subcutaneously at two inoculation levels (5 × 10^9 CFU/mL and 5 × 10^10 CFU/mL). (Leya et al, 2018)
• Description: This study explores the efficacy of a Salmonella Typhimurium delivery-based combination vaccine expressing four heterologous Brucella antigens targeting brucellosis in goats. Efficacy: Immunized goats showed significantly higher protection demonstrated by lower bacterial loads in most tissues, reduced expression of Brucella antigens in spleen, kidney, and lung, and ameliorated histopathological lesions compared to non-immunized controls. Immune response: Significantly higher serum IgG titers against individual Brucella antigens and elevated interferon-γ production from peripheral blood mononuclear cells in vaccinated groups compared to non-immunized goats. (Leya et al, 2018)

Goat Response

• Immune Response: Significantly higher serum IgG titers against individual Brucella antigens and elevated interferon-γ production from peripheral blood mononuclear cells in vaccinated groups compared to non-immunized goats. (Leya et al, 2018)
• Challenge Protocol: Immunization of goats followed by challenge with virulent Brucella abortus at 6 weeks post-immunization; measurement of serum IgG titers, interferon-γ production from peripheral blood mononuclear cells, bacterial loads in tissues, relative real-time PCR for antigen expression, and histopathological lesion assessment. (Leya et al, 2018)
• Efficacy: Immunized goats showed significantly higher protection demonstrated by lower bacterial loads in most tissues, reduced expression of Brucella antigens in spleen, kidney, and lung, and ameliorated histopathological lesions compared to non-immunized controls. (Leya et al, 2018)
• Description: Immunization of goats followed by challenge with virulent Brucella abortus at 6 weeks post-immunization; measurement of serum IgG titers, interferon-γ production from peripheral blood mononuclear cells, bacterial loads in tissues, relative real-time PCR for antigen expression, and histopathological lesion assessment. (Leya et al, 2018)